Taiwan Stock Exchange · Healthcare
Bora Pharmaceuticals stock from India: price, numbers and tax
Bora Pharmaceuticals (6472) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Bora Pharmaceuticals at a glance
- Price
- NT$429.50+NT$5.50 (1.30%)
- Market cap
- NT$54.71B
- Day range
- NT$426.50 – NT$445.50
- P/E
- 35.03
- Dividend yield
- 2.33%
- Volume
- 619.22K
- 1 month
- -0.81%
- 6 months
- -2.16%
- YTD
- -11.99%
- 1 year
- -37.75%
- 5 years
- —
Bora Pharmaceuticals statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$19.0B | NT$19.2B | NT$14.2B | NT$10.5B | NT$4.9B |
| Gross profit | NT$7.7B | NT$7.7B | NT$7.0B | NT$2.9B | NT$1.7B |
| Operating income | NT$3.3B | NT$3.4B | NT$5.2B | NT$1.9B | NT$1.1B |
| Net income | NT$3.0B | NT$3.9B | NT$3.0B | NT$1.4B | NT$749.7M |
| Earnings per share | NT$23.90 | NT$32.14 | NT$25.19 | NT$11.89 | NT$6.45 |
| EBITDA | NT$4.2B | NT$6.5B | NT$5.7B | NT$2.3B | NT$1.3B |
| Total assets | NT$44.7B | NT$45.6B | NT$25.1B | NT$22.8B | NT$7.4B |
| Total debt | NT$18.2B | NT$19.0B | NT$5.0B | NT$7.6B | NT$2.2B |
| Cash and short-term investments | NT$5.1B | NT$5.9B | NT$3.4B | NT$3.5B | NT$910.8M |
| Shareholders' equity | NT$15.4B | NT$12.9B | NT$9.1B | NT$4.5B | NT$3.2B |
| Operating cash flow | NT$4.2B | NT$980.8M | NT$4.6B | NT$2.0B | NT$1.2B |
| Free cash flow | NT$3.3B | NT$293.8M | NT$3.2B | NT$1.8B | NT$873.1M |
| Capital expenditure | −NT$928.7M | −NT$687.0M | −NT$1.4B | −NT$200.2M | −NT$363.6M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Lotus Pharmaceutical | 1795.TW | NT$177.00 | NT$46.52B |
| Handa Pharmaceuticals | 6620.TWO | $145.00 | $24.15B |
| TTY Biopharm | 4105.TWO | $78.40 | $19.49B |
| Synmosa Biopharma | 4114.TWO | $29.50 | $15.92B |
| YungShin Global | 3705.TW | NT$56.40 | NT$15.02B |
| Grape King Bio | 1707.TW | NT$85.30 | NT$12.64B |
| Standard Chem & Pharm | 1720.TW | NT$56.10 | NT$11.03B |
| SCI Pharmtech | 4119.TW | NT$55.60 | NT$6.64B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Bora Pharmaceuticals from India
What Bora Pharmaceuticals does
Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including Sales, Contract Development & Manufacturing Organization (CDMO), and other ancillary services. Bora Pharmaceuticals operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Bora Pharmaceuticals shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.